Clearside Biomedical Stock Fundamentals
| CLSD Stock | USD 1.07 0.01 0.93% |
Clearside Biomedical fundamentals help investors to digest information that contributes to Clearside Biomedical's financial success or failures. It also enables traders to predict the movement of Clearside Stock. The fundamental analysis module provides a way to measure Clearside Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearside Biomedical stock.
At present, Clearside Biomedical's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 35.5 M, whereas EBIT is forecasted to decline to (24.3 M). Clearside | Select Account or Indicator |
Clearside Biomedical Company Current Valuation Analysis
Clearside Biomedical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Clearside Biomedical Current Valuation | 59.1 M |
Most of Clearside Biomedical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clearside Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Clearside Current Valuation Historical Pattern
Today, most investors in Clearside Biomedical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Clearside Biomedical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Clearside Biomedical current valuation as a starting point in their analysis.
Clearside Biomedical Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Clearside Biomedical has a Current Valuation of 59.1 M. This is 99.59% lower than that of the Pharmaceuticals sector and 98.73% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.64% higher than that of the company.
Clearside Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Clearside Biomedical's current stock value. Our valuation model uses many indicators to compare Clearside Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clearside Biomedical competition to find correlations between indicators driving Clearside Biomedical's intrinsic value. More Info.Clearside Biomedical is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Clearside Biomedical's Return On Equity is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Clearside Biomedical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Clearside Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clearside Biomedical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clearside Biomedical could also be used in its relative valuation, which is a method of valuing Clearside Biomedical by comparing valuation metrics of similar companies.Clearside Biomedical is currently under evaluation in current valuation category among its peers.
Clearside Fundamentals
| Return On Equity | -13.1 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (84.33) % | ||||
| Current Valuation | 59.1 M | ||||
| Shares Outstanding | 75.84 M | ||||
| Shares Owned By Insiders | 7.38 % | ||||
| Shares Owned By Institutions | 23.16 % | ||||
| Number Of Shares Shorted | 1.76 M | ||||
| Price To Earning | 130.00 X | ||||
| Price To Book | 3.93 X | ||||
| Price To Sales | 10.89 X | ||||
| Revenue | 8.23 M | ||||
| Gross Profit | 1.12 M | ||||
| EBITDA | (23.06 M) | ||||
| Net Income | (32.48 M) | ||||
| Cash And Equivalents | 29.03 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 43 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.56 X | ||||
| Book Value Per Share | (0.25) X | ||||
| Cash Flow From Operations | (18.14 M) | ||||
| Short Ratio | 1.21 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 30 | ||||
| Beta | 2.33 | ||||
| Market Capitalization | 81.91 M | ||||
| Total Asset | 34.02 M | ||||
| Retained Earnings | (320.92 M) | ||||
| Working Capital | 23.31 M | ||||
| Current Asset | 20.48 M | ||||
| Current Liabilities | 5.2 M | ||||
| Net Asset | 34.02 M |
About Clearside Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearside Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearside Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearside Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 75 K | 71.2 K | |
| Total Revenue | 8.2 M | 5.5 M | |
| Cost Of Revenue | 355 K | 337.2 K | |
| Stock Based Compensation To Revenue | 0.51 | 0.49 | |
| Sales General And Administrative To Revenue | 1.44 | 1.37 | |
| Research And Ddevelopement To Revenue | 2.53 | 2.41 | |
| Capex To Revenue | 0.22 | 0.21 | |
| Revenue Per Share | 0.13 | 0.10 | |
| Ebit Per Revenue | (3.02) | (3.17) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:Check out Clearside Biomedical Piotroski F Score and Clearside Biomedical Altman Z Score analysis. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.91) | Return On Assets (0.44) | Return On Equity (13.10) |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.